Testing A New Model For Personalized Drug Development
This article was originally published in RPM Report
Executive Summary
Pfizer, Genentech, AstraZeneca and Amgen drugs will be studied in a lung cancer “master protocol” set to launch March 1. The trial could revolutionize the treatment of a rare, serious disease – but advocates have an even bigger goal: “changing the entire paradigm for drug development.”
You may also be interested in...
FDA Eager For More Master Protocols in Oncology: Approach Means Lower Cost For Sponsors—and Less Control
FDA officials are enthusiastic about broad, multi-agent cancer trials built on the I-SPY model. For sponsors, the trials mean less control over the development path and ultimate value proposition for the therapy—but may have important benefits on defending high prices for truly effective new therapies.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Cost-Based Pricing: The Real Threat Hiding In Latest US Drug Price Headlines
Bernie Sanders is back at it, getting headlines for demanding immediate price cuts to Novo’s blockbuster GLP-1 brands. But behind the familiar rhetoric is a newer threat: academic research on cost-based pricing that could one day feed into the emerging Medicare ‘negotiation’ system.